home / stock / cydy / cydy quote
Last: | $0.135 |
---|---|
Change Percent: | -0.55% |
Open: | $0.134 |
Close: | $0.13575 |
High: | $0.139 |
Low: | $0.134 |
Volume: | 460,222 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.135 | $0.134 | $0.13575 | $0.139 | $0.134 | 460,222 | 07-05-2024 |
$0.1358 | $0.14 | $0.13575 | $0.143 | $0.1321 | 2,042,396 | 07-04-2024 |
$0.13575 | $0.14 | $0.13575 | $0.143 | $0.1321 | 2,042,396 | 07-03-2024 |
$0.13635 | $0.1376 | $0.13635 | $0.1399 | $0.134 | 655,121 | 07-02-2024 |
$0.1376 | $0.137 | $0.1376 | $0.144 | $0.1351 | 670,333 | 07-01-2024 |
$0.139 | $0.1499 | $0.139 | $0.15 | $0.131243 | 3,337,139 | 06-28-2024 |
$0.14875 | $0.14975 | $0.14875 | $0.15 | $0.1476 | 1,255,585 | 06-27-2024 |
$0.145125 | $0.1399 | $0.145125 | $0.157 | $0.1362 | 2,576,878 | 06-26-2024 |
$0.1375 | $0.14 | $0.1375 | $0.1474 | $0.1356 | 667,553 | 06-25-2024 |
$0.1398 | $0.144 | $0.1398 | $0.144 | $0.133 | 631,048 | 06-24-2024 |
$0.14 | $0.1479 | $0.14 | $0.1479 | $0.1351 | 379,526 | 06-21-2024 |
$0.1362 | $0.1371 | $0.1362 | $0.153 | $0.1281 | 3,902,689 | 06-20-2024 |
$0.134 | $0.131 | $0.134 | $0.1398 | $0.1306 | 1,693,539 | 06-19-2024 |
$0.134 | $0.131 | $0.134 | $0.139832 | $0.1306 | 1,693,539 | 06-18-2024 |
$0.131 | $0.1342 | $0.131 | $0.137 | $0.1275 | 2,881,356 | 06-17-2024 |
$0.1341 | $0.142 | $0.1341 | $0.142 | $0.1311 | 3,709,408 | 06-14-2024 |
$0.1369 | $0.145 | $0.1369 | $0.1471 | $0.1361 | 2,480,695 | 06-13-2024 |
$0.1371 | $0.145 | $0.1371 | $0.145 | $0.1355 | 3,112,714 | 06-12-2024 |
$0.1403 | $0.1501 | $0.1403 | $0.1545 | $0.1371 | 9,213,058 | 06-11-2024 |
$0.15 | $0.1524 | $0.15 | $0.1575 | $0.1441 | 2,369,998 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...
VANCOUVER, Washington, May 16, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, I write today to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), as we approach the end of our 2024 fiscal year (May 31, 2024), and to sincerely thank you for your unwavering...